Ophthotech (NASDAQ: OPHT) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Ophthotech to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Risk & Volatility
Ophthotech has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Ophthotech’s peers have a beta of 2.36, indicating that their average share price is 136% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Ophthotech and its peers, as provided by MarketBeat.
||Strong Buy Ratings
Ophthotech presently has a consensus price target of $4.00, suggesting a potential upside of 40.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.66%. Given Ophthotech’s higher possible upside, analysts clearly believe Ophthotech is more favorable than its peers.
Insider & Institutional Ownership
62.5% of Ophthotech shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 2.0% of Ophthotech shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Ophthotech and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings and Valuation
This table compares Ophthotech and its peers revenue, earnings per share and valuation.
Ophthotech’s peers have higher revenue and earnings than Ophthotech. Ophthotech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Ophthotech peers beat Ophthotech on 8 of the 13 factors compared.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.